Mangalam Drugs & Organics Limited expands anti-malaria API portfolio with Pyronaridine

Mangalam Drugs & Organics Limited is expanding its anti-malaria API portfolio with the introduction of Pyronaridine, having recently received prestigious pre-qualification from WHO Geneva. The World Health Organization has endorsed the Pyronaridine and Artesunate combination for malaria treatment. and we are proud to be the second company, following the innovator, to achieve this significant milestone. This development will position us at the forefront of antimalaria API production globally and is expected to drive substantial growth and profitability for the Company.

Moreover, we are grateful for the support of the Bill and Melinda Gates Foundation (BMFG) in this project. We are currently collaborating with them for technical assistance to achieve backward integration of Pyronaridine, which will enhance the cost-competitiveness of this API in the coming years.

The Medicine for Malaria Venture (MMV), headquartered in Geneva, Switzerland, is a nonprofit organization dedicated to the development and support of innovative antimalarial therapies. MMV is actively engaged in advancing new treatments for malaria and is focused on optimizing combination therapies. The organization has endorsed the use of the pyronaridine-artesunate combination therapy as a recommended treatment for malaria. This combination leverages the synergistic effects of both drugs to enhance therapeutic efficacy and combat malaria more effectively.

Shares of Mangalam Drugs And Organics Limited was last trading in BSE at Rs. 121.20 as compared to the previous close of Rs. 114.75. The total number of shares traded during the day was 40564 in over 1040 trades.

The stock hit an intraday high of Rs. 124.25 and intraday low of 115.90. The net turnover during the day was Rs. 4900342.00.

Source : Equity Bulls

Keywords

MangalamDrugsAndOrganics INE584F01014 AntiMalaria APIPortfolio Pyronaridine